International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High-Risk Patients With Hypertrophic Cardiomyopathy.
In this international multicenter study, the largest to date, including >3300 consecutive patients with HCM and ICDs, device therapy terminated potentially lethal ventricular tachyarrhythmias in 1 of 6 patients, with low HCM-related mortality rates for patients with ICDs.
Abstract
Background
Implanted cardioverter-defibrillators (ICDs) have been used in patients with hypertrophic cardiomyopathy (HCM) to prevent sudden death, and have proven lifesaving for many patients. However, experience with ICD therapy has largely been derived from relatively small HCM cohorts confined to specific countries or regions of the world. Therefore, we sought to determine the effectiveness of ICDs in preventing sudden death due to life-threatening ventricular arrhythmias in a large international multicenter HCM population.
Methods
Databases from 25 HCM centers (8 in the United States, 9 in Europe, 4 in Asia, and 1 each in Australia, Africa, Mexico, and South America) were retrospectively interrogated to identify consecutive patients with HCM with ICDs (1992 to 2024) followed for 7±6 years (up to 32 years) for clinical outcomes.
Results
A total of 3387 patients were identified (63% men). They had a mean left ventricular thickness of 22±7 mm. The participants had received ICDs at a mean age of 47±17 years. Over follow-up, 550 patients (16%) experienced ≥1 appropriate ICD therapy (2.6%/y), including 86 of the 247 implanted for secondary prevention (35% [6.4%/y]) and 464 of the 3140 implanted for primary prevention (15% [2.2%/y]). Appropriate therapy occurred in the 464 primary prevention patients at a mean age of 49±17 years, with a median time to first appropriate therapy of 4 years after ICD implantation; 16% of these received their first appropriate therapy ≥10 years after implantation, and 47% experienced multiple interventions. Independent predictors of appropriate ICD therapy included unexplained syncope, left ventricular apical aneurysms, left ventricular systolic dysfunction, and nonsustained ventricular tachycardia on ambulatory monitoring. Of the 3140 primary prevention patients, 2946 survived (94%) and 194 died (6%) (0.8%/y), including 68 due to HCM (0.3%/y), predominantly of end-stage heart failure (n=43) or stroke (n=9). In contrast, 11 patients (0.4%) died suddenly, with device failures occurring in 2.4% of those with life-threatening ventricular tachyarrhythmias. Survival free from HCM-related mortality at 10 and 20 years was 97% and 91%, respectively.
Conclusions
In this international multicenter study, the largest to date, including >3300 consecutive patients with HCM and ICDs, device therapy terminated potentially lethal ventricular tachyarrhythmias in 1 of 6 patients, with low HCM-related mortality rates for patients with ICDs. These novel data demonstrate the effectiveness of the ICD initiative, which has probably favorably altered the natural history of many patients with HCM worldwide.
Implantable cardioverter-defibrillator (ICD) therapy is essential for preventing sudden cardiac death in patients with hypertrophic cardiomyopathy (HCM). However, real-world data regarding transvenous ICD (TV-ICD) and subcutaneous ICD (S-ICD) systems in patients with HCM remain limited.We retrospectively analyzed 279 p...
Yoshiyasu Aizawa, H. Hayashi, Hiroaki Hirayama et al.· International Heart Journal· 0 citations
Aim.
To identify clinical and instrumental factors associated with clinical outcomes in patients with implanted implantable cardioverterdefibrillators (ICD) / cardiac resynchronization therapy defibrillators (CRTD).
Material and methods.
A singlecenter retrospective registry included clinical and instrumental...
K. N. Kozaeva, E. Rimskaya, G. Tarasovskiy et al.· Journal of Arrhythmology· 0 citations
Implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) are effective in preventing sudden cardiac death. However, inappropriate shocks (Inap-S) may impair quality of life and have been associated with adverse clinical outcomes. This study evaluated the incidence...
J. Pereira, S. Andraz, L. Hamann et al.· Cardiology Plus· 0 citations
Introduction. Implantable cardioverter-defibrillators (ICDs) have been shown to reduce mortality in patients with both ischemic and non-ischemic cardiomyopathy (NICMP) by effectively terminating life-threatening ventricular arrhythmias. However, the distribution of ventricular arrhythmias varies across patient subgroup...
H. A. Z. Nassir, H. A. Swaid, A. Ibrahim· Кардиология в Беларуси· 0 citations
The incidence of sudden cardiac arrest recurrence following defibrillator implantation is high across all patient groups, regardless of aetiology, and sustained ventricular tachycardia as the indication for device implantation predicts a higher incidence.
Mara Adjic, F. Adjic, Nikolina Konstantinovic et al.· Medicinski pregled· 0 citations
In this analysis including a large cohort of post-myocardial infarction patients with reduced LVEF, the estimated mortality reduction associated with primary prevention ICD implantation progressively decreased over time.
Alireza Sepehri Shamloo, T. Chiba, J. G. Tijssen et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.